Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Mutational analysis of exome sequences from 150 lung adenocarcinomas

EF 2009-10

Résumé
Lung cancer is the leading cause of cancer-related death in Canada and only 15% of patients survive for more than 5 years. The most common form of lung cancer is non-small cell of which 60% are of the adenocarcinoma subtype most commonly seen in non-smokers. As smoking rates decline, adenocarcinomas represent an increasing proportion of lung cancer diagnoses and effective therapies are urgently needed to improve the survival of patients with this disease. Mutations, abnormal changes in DNA sequence, are frequently responsible for driving cancer development. These driver mutations are found primarily in coding exons, the portions of genes that encode proteins responsible for cellular function. Drugs that inhibit one such protein, EGFR, are highly effective in lung adenocarcinomas that harbour EGFR mutations. However, only 25% of lung adenocarcinomas have EGFR mutations, leaving little recourse for the majority of patients. To accelerate development of new treatments, there is a clear need to identify additional genes containing mutations that drive lung cancer. To uncover these mutations, I propose to sequence all known protein-coding genes in a set of 150 lung adenocarcinomas. The proposed method uses custom probes that separate all ~180,000 exons from the non-coding sequences that make up 99% of the human genome. Isolated exons are then sequenced simultaneously using a second-generation DNA sequencing device. Cancer mutations will be detected by comparing these sequences against the human genome reference sequence and by confirming their absence in DNA from matched non-cancerous cells. The frequency of more common mutations will then be determined in a larger set of 1,000 lung tumours. Variants in commonly mutated genes may be responsible for causing lung cancer and we will assess their effect on normal cells in the lab. Validated cancer drivers will represent promising drug targets and an opportunity to better understand lung cancer.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
193867
Name
Pugh Trevor J
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Mutational analysis of exome sequences from 150 lung adenocarcinomas
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adenocarcinoma; Bioinformatics; Cancer Drivers; Cancer Genomics; Dna Sequencing; Drug Targets; Exome; Lung Cancer; Mutations; Sequence Capture
Abstract
Lung cancer is the leading cause of cancer-related death in Canada and only 15% of patients survive for more than 5 years. The most common form of lung cancer is non-small cell of which 60% are of the adenocarcinoma subtype most commonly seen in non-smokers. As smoking rates decline, adenocarcinomas represent an increasing proportion of lung cancer diagnoses and effective therapies are urgently needed to improve the survival of patients with this disease. Mutations, abnormal changes in DNA sequence, are frequently responsible for driving cancer development. These driver mutations are found primarily in coding exons, the portions of genes that encode proteins responsible for cellular function. Drugs that inhibit one such protein, EGFR, are highly effective in lung adenocarcinomas that harbour EGFR mutations. However, only 25% of lung adenocarcinomas have EGFR mutations, leaving little recourse for the majority of patients. To accelerate development of new treatments, there is a clear need to identify additional genes containing mutations that drive lung cancer. To uncover these mutations, I propose to sequence all known protein-coding genes in a set of 150 lung adenocarcinomas. The proposed method uses custom probes that separate all ~180,000 exons from the non-coding sequences that make up 99% of the human genome. Isolated exons are then sequenced simultaneously using a second-generation DNA sequencing device. Cancer mutations will be detected by comparing these sequences against the human genome reference sequence and by confirming their absence in DNA from matched non-cancerous cells. The frequency of more common mutations will then be determined in a larger set of 1,000 lung tumours. Variants in commonly mutated genes may be responsible for causing lung cancer and we will assess their effect on normal cells in the lab. Validated cancer drivers will represent promising drug targets and an opportunity to better understand lung cancer.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Pugh, Trevor J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~